908 Devices' (MASS) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of 908 Devices (NASDAQ:MASS - Free Report) in a research note published on Thursday morning,Weiss Ratings reports.

Separately, Stephens reaffirmed an "overweight" rating and issued a $6.00 price target on shares of 908 Devices in a research note on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.

908 Devices Trading Down 0.7 %

Shares of 908 Devices stock traded down $0.04 on Thursday, reaching $5.43. The stock had a trading volume of 356,982 shares, compared to its average volume of 984,322. The business's 50 day moving average is $4.02 and its two-hundred day moving average is $3.12. 908 Devices has a 1 year low of $1.81 and a 1 year high of $7.48. The company has a market cap of $191.84 million, a P/E ratio of -3.07 and a beta of 0.30.

Hedge Funds Weigh In On 908 Devices

A number of institutional investors have recently modified their holdings of MASS. Prescott Group Capital Management L.L.C. purchased a new stake in 908 Devices during the fourth quarter valued at approximately $330,000. Needham Investment Management LLC grew its stake in 908 Devices by 100.0% in the 4th quarter. Needham Investment Management LLC now owns 200,000 shares of the company's stock valued at $440,000 after acquiring an additional 100,000 shares during the period. AWM Investment Company Inc. raised its position in shares of 908 Devices by 6.3% during the 4th quarter. AWM Investment Company Inc. now owns 1,673,924 shares of the company's stock worth $3,683,000 after purchasing an additional 99,594 shares during the last quarter. Deutsche Bank AG increased its position in shares of 908 Devices by 1,159.4% during the fourth quarter. Deutsche Bank AG now owns 99,239 shares of the company's stock worth $218,000 after purchasing an additional 91,359 shares in the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in shares of 908 Devices in the first quarter valued at about $338,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.